SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Tessera Therapeutics to Present Preclinical Data at Hematology Meeting

Tessera Therapeutics plans to present preclinical data on its in vivo sickle cell disease program and in vivo CAR-T applications at the 68th American Society of Hematology Annual Meeting.

SquawkNews Desk

Related stories

Thousands of US Flights Canceled and Delayed as Air Travel System Recovers Thousands of US flights were canceled or delayed as the air travel system slowly recovered from a shutdown. M impact | EQUITY | Nov 14, 2026, 06:37 PM UTC Lilly Phase 3 Trial Reports Average 21.4% BMI Reduction With Zepbound The SURMOUNT-ADOLESCENTS trial showed Zepbound reduced BMI by an average of 21.4% in adolescents aged 12 to under 18 with obesity. M impact | EQUITY | Nov 14, 2026, 05:01 PM UTC Lilly Phase 2 Data Show Eloratzp Weight Loss of Up to 54.1 Pounds Phase 2 data showed average weight loss of up to 54.1 pounds (23.3%) at 48 weeks in adults with obesity and type 2 diabetes. M impact | EQUITY | Nov 14, 2026, 05:01 PM UTC Novo Nordisk CagriSema Reduced Waist Circumference by 17.2–17.5 cm Both CagriSema doses reduced waist circumference by 17.2–17.5 cm, versus 3.6 cm with placebo. M impact | EQUITY | Nov 14, 2026, 05:00 PM UTC Novo Nordisk CagriSema Shows Weight Loss in REDEFINE 9 Trial At 68 weeks, average weight loss was 20.7% with 1.7 mg/1.7 mg and 21.0% with 1.0 mg/1.0 mg, versus 2.0% with placebo. M impact | EQUITY | Nov 14, 2026, 05:00 PM UTC Novo Nordisk Says CagriSema Reduced Waist Circumference Up to 17.5 cm Both CagriSema doses reduced waist circumference by 17.2–17.5 cm, versus 3.6 cm with placebo. M impact | EQUITY | Nov 14, 2026, 05:00 PM UTC